カテゴリ： GlobalData, アメリカ, 企業調査

Intrexon Corp (XON)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Intrexon Corp (XON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7981
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：119
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Intrexon Corp (Intrexon), formerly Genomatix Corp is a synthetic biology service provider. The company operates through its divisions and units such as cell engineering, data sciences and computational biology, information technology (IT), actobiotics, molecular engineering, agricultural biotech, animal sciences, and industrial products division. Its cell engineering unit designs and creates cell systems and optimize processes for the development of biologically based products to address unmet market needs. Intrexon’s IT division includes infrastructure, software engineering, and information systems. The company’s agricultural biotech division provides food and feed crops for a variety of applications in agriculture. It has partnership with the channel of network collaborators and joint ventures to commercialize its technologies. Intrexon is headquartered in Blacksburg, Virginia, the US.

Intrexon Corp (XON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Intrexon Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Intrexon Corp, Medical Devices Deals, 2012 to YTD 2018 12
Intrexon Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Intrexon Corp, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Intrexon Acquires Laboratory Operations From Codexis US$1.5 Million 16
Venture Financing 17
Intrexon Raises USD57.5 Million in Venture Financing 17
Intrexon Raises USD29 Million in Venture Financing 18
Intrexon Raises US$75 Million In Extended Series F Financing 19
ActoGeniX Raises US$14 Million In Series B Financing 20
Intrexon Raises Additional US$25 Million In Series F Financing 22
Medistem Raises Funds Through Venture Financing 23
Partnerships 24
Intrexon and Arch Pharmalabs Enter into Agreement 24
Intrexon and Johnson Matthey Enter into Agreement 25
ZIOPHARM, Intrexon Enter into Agreement with NCI 26
Intrexon Forms Joint Venture with White Rock Capital Partners 27
Intrexon Partners with Relieve Genetics 28
Intrexon Partners with Exotech Bio 29
Fibrocell Science Enters into Agreement with Intrexon 30
Intrexon Enters into Research Agreement with Janssen Pharma 31
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 32
Intrexon Enters into Partnership with Synthetic Biologics 33
Intrexon Enters into Co-Development Agreement with Oragenics 34
Intrexon Enters into R&D Agreement with National Cancer Institute 35
Ziopharm Expands Co-Development Agreement with Intrexon 36
Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 37
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 38
OvaScience Forms Joint Venture With Intrexon 39
Stallergenes Enters Into Co-Development Agreement With ActoGeniX 40
Stallergenes Exercises Option for Co-Development Agreement with ActoGeniX 41
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 42
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 44
Soligenix Enters Into Co-Development Agreement With Intrexon 45
Sanford-Burnham Medical Enters Into Agreement With Intrexon For Stem Cell Research 47
ActoGeniX Enters Into Research Agreement With Merck 48
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 49
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 50
Fibrocell Science Amends Co-Development Agreement with Intrexon 51
Medistem Enters Into Agreement With Superview Biotechnology To Develop Antibodies For Regenerative Therapies 52
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 53
BioLife Cell Bank Enters Into Research Agreement With Intrexon 54
Medistem Enters Into Co-Development Agreement With Shanghai Jia Fu Medical Apparatus 55
Licensing Agreements 56
Genten Therapeutics Enters Into Licensing Agreement With Intrexon 56
CRS Bio Enters into Licensing Agreement with Intrexon 57
Fibrocell Science Enters into Licensing Agreement with Intrexon 58
Intrexon Enters into Licensing Agreement with Merck Serono 60
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 61
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 63
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 65
ERCell Enters into Licensing Agreement with Medistem 67
Medistem Enters Into Licensing Agreement With Cytori Therapeutics 68
Medistem Enters Into Licensing Agreement With Yale University For Type 1 Diabetes 69
Equity Offering 70
Intrexon to Raise USD100 Million in Public Offering of Shares 70
Intrexon Raises USD86.2 Million in Public Offering of Shares 71
Intrexon to Raise USD100 Million in Private Placement of Preferred Shares 73
Oragenics Raises USD4.7 Million in Private Placement of Shares 74
Intrexon Raises USD230 Million in Public Offering of Shares 76
Intrexon Raises USD116.4 Million in Public Offering of Shares 78
Oragenics Completes Private Placement Of Shares For US$4 Million 80
Intrexon Completes IPO Of Shares For US$184 Million 81
Debt Offering 82
Intrexon Raises USD200 Million in Public Offering 3.50% Convertible Senior Notes Due 2023 82
Acquisition 83
Intrexon Acquires GenVec 83
Intrexon Acquires 100% Stake in Okanagan Specialty Fruits 85
Intrexon Acquires Remaining 41% Stake in Exemplar Genetics 86
Intrexon Acquires ActoGeniX 87
Intrexon Acquires 51% Stake in Exemplar Genetics 89
Intrexon Completes Acquisition Of MediStem For US$26 Million 90
Intrexon Corp – Key Competitors 91
Intrexon Corp – Key Employees 92
Intrexon Corp – Locations And Subsidiaries 93
Head Office 93
Other Locations & Subsidiaries 93
Joint Venture 94
Recent Developments 95
Strategy And Business Planning 95
Mar 10, 2017: Intrexon Creates Precigen and Accelerates Strategic Review of Structural Options Related to Health Assets 95
Financial Announcements 96
May 10, 2018: Intrexon Announces First Quarter 2018 Financial Results 96
Mar 01, 2018: Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results 99
Nov 09, 2017: Intrexon Announces Third Quarter 2017 Financial Results 102
Aug 09, 2017: Intrexon Announces Second Quarter and First Half 2017 Financial Results 105
May 10, 2017: Intrexon Announces First Quarter 2017 Financial Results 107
Mar 01, 2017: Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results 109
Corporate Communications 112
Nov 27, 2017: Intrexon Announces Key Management Appointments 112
Jun 29, 2017: Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen 114
Apr 27, 2017: Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors 115
Other Significant Developments 116
Aug 09, 2018: Intrexon business update and conference call 116
May 29, 2018: Isolation and Recombinant Expression of Key Enzyme for Opioid Production 118
Appendix 119
Methodology 119
About GlobalData 119
Contact Us 119
Disclaimer 119

List of Tables
Intrexon Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Intrexon Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Intrexon Corp, Deals By Therapy Area, 2012 to YTD 2018 11
Intrexon Corp, Medical Devices Deals, 2012 to YTD 2018 12
Intrexon Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Intrexon Acquires Laboratory Operations From Codexis US$1.5 Million 16
Intrexon Raises USD57.5 Million in Venture Financing 17
Intrexon Raises USD29 Million in Venture Financing 18
Intrexon Raises US$75 Million In Extended Series F Financing 19
ActoGeniX Raises US$14 Million In Series B Financing 20
Intrexon Raises Additional US$25 Million In Series F Financing 22
Medistem Raises Funds Through Venture Financing 23
Intrexon and Arch Pharmalabs Enter into Agreement 24
Intrexon and Johnson Matthey Enter into Agreement 25
ZIOPHARM, Intrexon Enter into Agreement with NCI 26
Intrexon Forms Joint Venture with White Rock Capital Partners 27
Intrexon Partners with Relieve Genetics 28
Intrexon Partners with Exotech Bio 29
Fibrocell Science Enters into Agreement with Intrexon 30
Intrexon Enters into Research Agreement with Janssen Pharma 31
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 32
Intrexon Enters into Partnership with Synthetic Biologics 33
Intrexon Enters into Co-Development Agreement with Oragenics 34
Intrexon Enters into R&D Agreement with National Cancer Institute 35
Ziopharm Expands Co-Development Agreement with Intrexon 36
Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 37
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 38
OvaScience Forms Joint Venture With Intrexon 39
Stallergenes Enters Into Co-Development Agreement With ActoGeniX 40
Stallergenes Exercises Option for Co-Development Agreement with ActoGeniX 41
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 42
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 44
Soligenix Enters Into Co-Development Agreement With Intrexon 45
Sanford-Burnham Medical Enters Into Agreement With Intrexon For Stem Cell Research 47
ActoGeniX Enters Into Research Agreement With Merck 48
Fibrocell Science Enters Into Co-Development Agreement With Intrexon 49
Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 50
Fibrocell Science Amends Co-Development Agreement with Intrexon 51
Medistem Enters Into Agreement With Superview Biotechnology To Develop Antibodies For Regenerative Therapies 52
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 53
BioLife Cell Bank Enters Into Research Agreement With Intrexon 54
Medistem Enters Into Co-Development Agreement With Shanghai Jia Fu Medical Apparatus 55
Genten Therapeutics Enters Into Licensing Agreement With Intrexon 56
CRS Bio Enters into Licensing Agreement with Intrexon 57
Fibrocell Science Enters into Licensing Agreement with Intrexon 58
Intrexon Enters into Licensing Agreement with Merck Serono 60
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 61
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 63
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 65
ERCell Enters into Licensing Agreement with Medistem 67
Medistem Enters Into Licensing Agreement With Cytori Therapeutics 68
Medistem Enters Into Licensing Agreement With Yale University For Type 1 Diabetes 69
Intrexon to Raise USD100 Million in Public Offering of Shares 70
Intrexon Raises USD86.2 Million in Public Offering of Shares 71
Intrexon to Raise USD100 Million in Private Placement of Preferred Shares 73
Oragenics Raises USD4.7 Million in Private Placement of Shares 74
Intrexon Raises USD230 Million in Public Offering of Shares 76
Intrexon Raises USD116.4 Million in Public Offering of Shares 78
Oragenics Completes Private Placement Of Shares For US$4 Million 80
Intrexon Completes IPO Of Shares For US$184 Million 81
Intrexon Raises USD200 Million in Public Offering 3.50% Convertible Senior Notes Due 2023 82
Intrexon Acquires GenVec 83
Intrexon Acquires 100% Stake in Okanagan Specialty Fruits 85
Intrexon Acquires Remaining 41% Stake in Exemplar Genetics 86
Intrexon Acquires ActoGeniX 87
Intrexon Acquires 51% Stake in Exemplar Genetics 89
Intrexon Completes Acquisition Of MediStem For US$26 Million 90
Intrexon Corp, Key Competitors 91
Intrexon Corp, Key Employees 92
Intrexon Corp, Subsidiaries 93
Intrexon Corp, Joint Venture 94

List of Figures
Intrexon Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Intrexon Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Intrexon Corp, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Intrexon Corp (XON)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Tanabe Research Laboratories USA Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Tanabe Research Laboratories USA Inc (Tanabe Research Laboratories USA), a subsidiary of Mitsubishi Tanabe Pharma Corp is a healthcare research center that discovers and develops biological drugs. The laboratory conducts research on metabolics, immunology and inflammation. Its products are u …
  • Tel Aviv Sourasky Medical Center：製薬・医療：M&Aディール及び事業提携情報
    Summary Tel Aviv Sourasky Medical Center (Sourasky Medical) is an academic medical center that provides patient-centered care, research and education services. The center offers services in the areas of cardiology, dermatology, gastroenterology, general surgery, genetics, emergency medicine, rheumat …
  • Trustco Group Holdings Limited：企業の戦略・SWOT・財務情報
    Trustco Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Trustco Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Weyerhaeuser Company：企業の戦略・SWOT・財務情報
    Weyerhaeuser Company - Strategy, SWOT and Corporate Finance Report Summary Weyerhaeuser Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Futura Medical Plc (FUM)：製薬・医療：M&Aディール及び事業提携情報
    Summary Futura Medical Plc (Futura Medical) is a pharmaceutical company that focuses on research and development of novel products for various therapeutic areas, including sexual health and pain relief management. The company focuses on developing pharmaceutical products based on its transdermal dru …
  • Natra S.A.：企業の戦略・SWOT・財務情報
    Natra S.A. - Strategy, SWOT and Corporate Finance Report Summary Natra S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Ameren Corporation (AEE)：電力：M&Aディール及び事業提携情報
    Summary Ameren Corporation (Ameren) is a public utility holding company that generates, transmits and distributes electricity; and transmits and distributes natural gas through its subsidiaries. The company generates electricity through varied energy sources such as coal, nuclear, hydro, solar, natu …
  • Spanish National Cancer Research Center：製薬・医療：M&Aディール及び事業提携情報
    Summary Spanish National Cancer Research Center (CNIO) is a medical research center that conducts cancer research programs. The center integrates basic and translational cancer research. It conducts various scientific programs, which include molecular oncology program, structural biology and biocomp …
  • DeepOcean Group Holding BV：企業の戦略的SWOT分析
    DeepOcean Group Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Northern Trust Corporation：企業のM&A・事業提携・投資動向
    Northern Trust Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Northern Trust Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Nippon Soda Co., Ltd. (4041)：企業の財務・戦略的SWOT分析
    Nippon Soda Co., Ltd. (4041) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Graham Holdings Company (GHC)：企業の財務・戦略的SWOT分析
    Graham Holdings Company (GHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Arab National Bank：企業の戦略・SWOT・財務情報
    Arab National Bank - Strategy, SWOT and Corporate Finance Report Summary Arab National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Gulfsands Petroleum Plc：石油・ガス：M&Aディール及び事業提携情報
    Summary Gulfsands Petroleum Plc (Gulfsands) is an oil and gas company that offers exploration, development, and production services. The company carries out acquisition, exploration, develops, and produces oil and natural gas. It holds interests in oil exploration and development projects in the Syr …
  • Korea Electric Power Corp：企業の発電所・SWOT分析2018
    Korea Electric Power Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • TPF SA：企業の戦略的SWOT分析
    TPF SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • TELUS Corporation：企業の戦略・SWOT・財務情報
    TELUS Corporation - Strategy, SWOT and Corporate Finance Report Summary TELUS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ITOCHU Corporation：企業のM&A・事業提携・投資動向
    ITOCHU Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ITOCHU Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Beneo GmbH：企業の戦略・SWOT・財務情報
    Beneo GmbH - Strategy, SWOT and Corporate Finance Report Summary Beneo GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Ingram Micro Inc.：企業の戦略・SWOT・財務情報
    Ingram Micro Inc. - Strategy, SWOT and Corporate Finance Report Summary Ingram Micro Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆